Company Information

  

Address: 1010 ATLANTIC AVENUE
SUITE 102 
City: ALAMEDA 
State: CA 
Zip Code: 94501 
Telephone: 510-521-3390 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

BioTime is a clinical-stage biotechnology company targeting degenerative diseases. Our programs are based on two core proprietary technology platforms: cell replacement and cell/drug delivery. With our cell replacement platform, we are creating new cells and tissues with our pluripotent and progenitor cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases. Our cell/drug delivery programs are based upon our proprietary HyStem® cell and drug delivery matrix technology. HyStem® was designed to provide for the transfer, retention, engraftment and metabolic support of cellular replacement therapy. Our lead cell replacement clinical program is OpRegen®, a retinal pigment epithelium cell replacement therapy, is in a Phase I/IIa, multicenter trial for the treatment of late-stage, dry age-related macular degeneration (dry-AMD).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.13NAN/E
12/2017-0.17NAN/E
09/2017-0.75NAN/E
06/2017-0.57NAN/E
03/2017-0.18NAN/E
12/2016-0.83NAN/E
09/20160.23NA16.96
06/2016-0.26NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.05Total Liab/Total Assets0.06
Net Inc/Total Assets-0.12Total Liab/Inv Cap0.06
Net Inc/Inv Cap-0.12Total Liab/Comm Equity0.03
Pretax Inc/Net Sales-6.73Interest Coverage Ratio-32.65
Net Inc/Net Sales-5.78Curr Debt/Equity0.00
Cash Flow/Net Sales-8.83LTD/Equity0.01
SG&A/NetSales5.76Total Debt/Equity0.01
Asset Utilization   Liquidity  
Net Receivables Turnover1.65Quick Ratio6.20
Inventory TurnoverNACurrent Ratio6.20
Inventory Day SalesNANet Rec/Curr Assets0.07
Net Sales/Work Cap0.10Inv/Curr AssetsNA
Net Sales/PP&E0.62  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.70 1.00 1.69 0.38
Cost of Goods Sold 0.11 0.05 0.05 0.01
Selling & Admin Exps 6.04 5.81 4.59 4.42
Operating Income -12.19 -9.56 -7.76 -10.32
Interest Exp NA -0.04 0.01 0.72
Pretax Income -63.70 -76.84 18.76 -16.10
Other Income 0.04 0.25 -2.94 2.37
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -63.55 -71.93 14.32 -11.65

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 31.38 38.18 18.17 20.87
Receivables - Total 3.00 3.05 3.70 3.07
Inventories - Total NA NA NA NA
Total Current Assets 36.13 42.62 23.23 25.53
Net Property, Plant & Equipment 5.37 5.53 5.42 5.24
Total Assets 110.40 173.24 221.87 193.35
Liabilities        
Accounts Payable 4.70 5.72 5.36 5.13
Debt in Current Liabilities 0.34 0.36 0.14 2.68
Total Current Liabilities 5.81 6.88 6.01 13.53
Long-Term Debt 1.09 1.17 1.30 1.40
Total Liabilities 10.43 10.60 23.58 17.23
Stockholder's Equity        
Minority Interest 2.49 1.62 10.70 2.06
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 379.19 378.49 342.51 334.54
Retained Earnings -279.42 -216.30 -144.36 -158.68
Treasury Stock NA 0.00 0.00 0.00
Total Stockholders' Equity 99.97 162.64 198.29 176.13
Total Liabilities and Stockholders' Equity 110.40 173.24 221.87 193.35

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -10.34 -5.68 -7.68 -9.06
Net Cash Provided by Investing Activities 2.21 -0.58 4.84 -5.33
Net Cash Provided by Financing Activities 0.63 26.38 4.99 4.92

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20134.43-43.88-0.76
12/20145.24-36.41-0.52
12/20157.04-46.99-0.55
12/20165.9233.57-0.83
12/20173.46-19.98-0.17
Growth Rates-6.03----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1812556,44444.49




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.